Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Surufatinib,Serplulimab,Etoposide,Carboplatin

"In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed."

Trial Locations (1)

350000

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
collaborator

Hunan Cancer Hospital

OTHER

collaborator

Wuhan TongJi Hospital

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV